Their targets were acetylcholinesterase (AChE), prostaglandin-endoperoxide synthase 2 (PTGS2), peroxisome proliferator activated receptor γ (PPARγ), IL-1β, glycogen synthase kinase 3 beta (GSK3B), etc. However, these active compounds were docked with AChE, a target which is less likely to be responsible for cognitive deficits as observed in clinical studies, which show Aricept had limited effect on AD (Birks and Harvey, 2018). This evidence concerns the gene ACHE and Cognitive impairment.